Login to Your Account

Will Nanobody Be Son of Humira?

Abbvie Helps Ablynx ‘Grow Up’ with $840M Collaboration

By Nuala Moran
Staff Writer

Wednesday, September 25, 2013
LONDON – Ablynx NV signed an $840 million licensing deal with Abbvie Inc. for its ALX-0061 nanobody targeted against the cytokine interleukin-6 receptor (IL-6R), in the treatment of rheumatoid arthritis and systemic lupus erythematosus.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription